Skip to main content
SpringerLink
Log in

Biochanin A: Understanding the Complexities in the Paradoxical Drug–Drug Interaction Potential

  • Review
  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Abstract

Use of dietary products is on the rise due to health benefits associated with the ingestion of flavonoids contained in them. Biochanin A (BioA) is the major constituent of red clover extract and has undergone investigations for health benefits and drug interaction potential. In many instances, BioA has exhibited a clear anomaly in the in vivo pharmacokinetics of co-administered drugs which were contrary to the in vitro studies. The focus of this review is to critically evaluate several mechanisms that may come into play for the interpretation of the in vivo pharmacokinetic data of drugs co-administered with BioA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Middleton E Jr, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer. Pharmacol Rev. 2000;52:673–751.

    CAS  PubMed  Google Scholar 

  2. Blair CK, Kelly AS, Steinberger J, Eberly LE, Napurski C, Robien K, Neglia JP, Mulrooney DA, Ross JA. Feasibility and preliminary efficacy of the effects of flavanoid-rich purple grape juice on the vascular health of childhood cancer survivors: a randomized, controlled crossover trial. Pediatr Blood Cancer. 2014;61(12):2290–6.

    Article  CAS  PubMed  Google Scholar 

  3. Martinez-Perez C, Ward C, Cook G, Mullen P, McPhail D, Harrison DJ, Langdon SP. Novel flavonoids as anti-cancer agents: mechanisms of action and promise for their potential application in breast cancer. Biochem Soc Trans. 2014;42(4):1017–23.

    Article  PubMed  Google Scholar 

  4. Shibata C, Ohno M, Otsuka M, Kishikawa T, Goto K, Muroyama R, Kato N, Yoshikawa T, Takata A, Koike K. The flavonoid apigenin inhibits hepatitis C virus replication by decreasing mature microRNA122 levels. Virology. 2014;462–463:42–8.

    Article  PubMed  Google Scholar 

  5. Zhao J, Tang W, Wang J, Xiang J, Gong H, Chen G. Pharmacokinetic and pharmacodynamic studies of four major phytochemical components of Da-Cheng-Qi decoction to treat acute pancreatitis. J Pharmacol Sci. 2013;122(2):118–27.

    Article  CAS  PubMed  Google Scholar 

  6. Pan H, Zhou W, He W, Liu X, Ding Q, Ling L, Zha X, Wang S. Genistein inhibits MDA-MB-231 triple-negative breast cancer cell growth by inhibiting NF-κB activity via the Notch-1 pathway. Int J Mol Med. 2012;30(2):337–43.

    CAS  PubMed  Google Scholar 

  7. Howells LM, Britton RG, Mazzoletti M, Greaves P, Broggini M, Brown K, Steward WP, Gescher AJ, Sale S. Preclinical colorectal cancer chemopreventive efficacy and p53-modulating activity of 3′,4′,5′-trimethoxyflavonol, a quercetin analogue. Cancer Prev Res (Phila). 2010;3(8):929–39.

    Article  CAS  Google Scholar 

  8. Moon YJ, Shin BS, An G, Morris ME. Biochanin A inhibits breast cancer tumor growth in a murine xenograft model. Pharm Res. 2008;25(9):2158–63.

    Article  CAS  PubMed  Google Scholar 

  9. Shapiro GI. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin Cancer Res. 2004;10(12 Pt 2):4270s–5s.

    Article  CAS  PubMed  Google Scholar 

  10. Brantley SJ, Argikar AA, Lin YS, Nagar S, Paine MF. Herb–drug interactions: challenges and opportunities for improved predictions. Drug Metab Dispos. 2014;42(3):301–17.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Sehm T, Fan Z, Weiss R, Schwarz M, Engelhorn T, Hore N, Doerfler A, Buchfelder M, Eyüpoglu IY, Savaskan NE. The impact of dietary isoflavonoids on malignant brain tumors. Cancer Med. 2014;3(4):865–77.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Jain A, Lai JC, Bhushan A. Biochanin A inhibits endothelial cell functions and proangiogenic pathways: implications in glioma therapy. Anticancer Drugs. 2015;26(3):323–30.

    Article  CAS  PubMed  Google Scholar 

  13. Puthli A, Tiwari R, Mishra KP. Biochanin A enhances the radiotoxicity in colon tumor cells in vitro. J Environ Pathol Toxicol Oncol. 2013;32(3):189–203.

    Article  CAS  PubMed  Google Scholar 

  14. Bhardwaj V, Tadinada SM, Jain A, Sehdev V, Daniels CK, Lai JC, Bhushan A. Biochanin A reduces pancreatic cancer survival and progression. Anticancer Drugs. 2014;25(3):296–302.

    Article  CAS  PubMed  Google Scholar 

  15. Sehdev V, Lai JC, Bhushan A. Biochanin A modulates cell viability, invasion, and growth promoting signaling pathways in HER-2-positive breast cancer cells. J Oncol. 2009 (article id#121458).

  16. Zhang S, Morris ME. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther. 2003;304:1258–67.

    Article  CAS  PubMed  Google Scholar 

  17. Zhang S, Morris ME. Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells. Pharm Res. 2003;20:1184–91.

    Article  CAS  PubMed  Google Scholar 

  18. Zhang S, Yang X, Morris ME. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol. 2004;65:1208–16.

    Article  CAS  PubMed  Google Scholar 

  19. Srinivas NR. Baicalin, an emerging multi-therapeutic agent: pharmacodynamics, pharmacokinetics, and considerations from drug development perspectives. Xenobiotica. 2010;40(5):357–67.

    Article  CAS  PubMed  Google Scholar 

  20. Azizi R, Goodarzi MT, Salemi Z. Effect of biochanin a on serum visfatin level of streptozocin-induced diabetic rats. Iran Red Crescent Med J. 2014;16(9):e15424.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Wang L, Waltenberger B, Pferschy-Wenzig EM, Blunder M, Liu X, Malainer C, Blazevic T, Schwaiger S, Rollinger JM, Heiss EH, Schuster D, Kopp B, Bauer R, Stuppner H, Dirsch VM, Atanasov AG. Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review. Biochem Pharmacol. 2014;92:73–89.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Hanski L, Genina N, Uvell H, Malinovskaja K, Gylfe A, Laaksonen T, Kolakovic R, Mäkilä E, Salonen J, Hirvonen J, Elofsson M, Sandler N, Vuorela PM. Inhibitory activity of the isoflavone biochanin A on intracellular bacteria of genus Chlamydia and initial development of a buccal formulation. PLoS One. 2014;9(12):e115115.

    Article  PubMed Central  PubMed  Google Scholar 

  23. Wu DQ, Zhong HM, Ding QH, Ba L. Protective effects of biochanin A on articular cartilage: in vitro and in vivo studies. BMC Complement Altern Med. 2014;14:444.

    Article  PubMed Central  PubMed  Google Scholar 

  24. Wang L, Waltenberger B, Pferschy-Wenzig EM, Blunder M, Liu X, Malainer C, Blazevic T, Schwaiger S, Rollinger JM, Heiss EH, Schuster D, Kopp B, Bauer R, Stuppner H, Dirsch VM, Atanasov AG. Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review. Biochem Pharmacol. 2014;92(1):73–89.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Marín L, Miguélez EM, Villar CJ, Lombó F. Bioavailability of dietary polyphenols and gut microbiota metabolism: antimicrobial properties. Biomed Res Int. 2015;2015:905215.

    Article  PubMed Central  PubMed  Google Scholar 

  26. Moon YJ, Sagawa K, Frederick K, Zhang S, Morris ME. Pharmacokinetics and bioavailability of the isoflavone biochanin A in rats. AAPS J. 2006;8(3):E433–42.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Hu M, Krausz K, Chen J, Ge X, Li J, Gelboin HL, Gonzalez FJ. Identification of CYP1A2 as the main isoform for the phase I hydroxylated metabolism of genistein and a prodrug converting enzyme of methylated isoflavones. Drug Metab Dispos. 2003;31(7):924–31.

    Article  CAS  PubMed  Google Scholar 

  28. Chen J, Halls SC, Alfaro JF, Zhou Z, Hu M. Potential beneficial metabolic interactions between tamoxifen and isoflavones via cytochrome P450-mediated pathways in female rat liver microsomes. Pharm Res. 2004;21(11):2095–104.

    Article  CAS  PubMed  Google Scholar 

  29. Kosaka K, Sakai N, Endo Y, Fukuhara Y, Tsuda-Tsukimoto M, Ohtsuka T, Kino I, Tanimoto T, Takeba N, Takahashi M, Kume T. Impact of intestinal glucuronidation on the pharmacokinetics of raloxifene. Drug Metab Dispos. 2011;39(9):1495–502.

    Article  CAS  PubMed  Google Scholar 

  30. Jia X, Chen J, Lin H, Hu M. Disposition of flavonoids via enteric recycling: enzyme-transporter coupling affects metabolism of biochanin Aand formononetin and excretion of their phase II conjugates. J Pharmacol Exp Ther. 2004;310(3):1103–13.

    Article  CAS  PubMed  Google Scholar 

  31. Wang X, Wolkoff AW, Morris ME. Flavonoids as a novel class of human organic anion-transporting polypeptide OATP1B1 (OATP-C) modulators. Drug Metab Dispos. 2005;33:1666–72.

    Article  CAS  PubMed  Google Scholar 

  32. An G, Morris ME. Effects of the isoflavonoid biochanin A on the transport of mitoxantrone in vitro and in vivo. Biopharm Drug Dispos. 2010;31:340–50.

    CAS  PubMed  Google Scholar 

  33. Peng SX, Ritchie DM, Cousineau M, Danser E, Dewire R, Floden J. Altered oral bioavailability and pharmacokinetics of P-glycoprotein substrates by coadministration of biochanin A. J PharmSci. 2006;95:1984–93.

    CAS  Google Scholar 

  34. Han HK, Lee HK. Improved effectiveness of biochanin A as a P-gp inhibitor in solid dispersion. Pharmazie. 2011;66:710–5.

    CAS  PubMed  Google Scholar 

  35. Lucas AN, Nation RL, Milne RW, Reynolds GD, Evans AM. The effects of phytoestrogenic isoflavones on the formation and disposition of paracetamol sulfate in the isolated perfused rat liver. J Pharm Pharmacol. 2003;55(5):639–46.

    Article  CAS  PubMed  Google Scholar 

  36. Singh SP, Wahajuddin Raju KS, Ali MM, Kohli K, Jain GK. Reduced bioavailability of tamoxifen and its metabolite 4-hydroxytamoxifen after oral administration with biochanin A (an isoflavone) in rats. Phytother Res. 2012;26(2):303–7.

    Article  CAS  PubMed  Google Scholar 

  37. Zhang S, Sagawa K, Arnold RD, Tseng E, Wang X, Morris ME. Interactions between the flavonoid biochanin A and P-glycoprotein substrates in rats: in vitro and in vivo. J Pharm Sci. 2010;99(1):430–41.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The author has no conflict of interest to report. The author has not received any financial help in the preparation of the manuscript.

Author information

Authors and Affiliations

  1. Department of Pharmacokinetics and Biopharmaceutics, Dr. Reddy’s Institute of Life Sciences, Gachibowli, Hyderabad, 500046, Andhra Pradesh, India

    Nuggehally R. Srinivas

Authors
  1. Nuggehally R. Srinivas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nuggehally R. Srinivas.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Srinivas, N.R. Biochanin A: Understanding the Complexities in the Paradoxical Drug–Drug Interaction Potential. Eur J Drug Metab Pharmacokinet 40, 119–125 (2015). https://doi.org/10.1007/s13318-015-0279-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13318-015-0279-0

Keywords

Search

Navigation